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Abstract
N0-ethyl-N0-nitrosourea (ENU) is a powerful germline mutagen used in conjunction with phenotype-driven screens to generate
novel mouse mutants. ENU also induces genetic lesions in somatic cells and dosage requires optimization between maximum
germline mutation rate versus induced sterility and tumourigenesis that compromise the welfare and fecundity of the ENU-
treated males. Here, we present our experience with BALB/cAnNCrl and C57BL/6J mice in terms of the pathology induced
by ENU and its impact on breeding. In both mouse strains, morbidity and mortality rises with ENU dose. In more than 75%
of C57BL/6J males, morbidity and mortality were attributable to the development of malignant T-lymphoblastic lymphoma.
Approximately 50% of ENU-treated BALB/cAnNCrl males develop early malignant T-lymphoblastic lymphoma, but the cohort
that survives develops late-onset lung carcinoma. Within strains, the latency of these clinically important tumour(s) was not
dosage-dependent, but the proportion of mice developing tumours and consequently removed from the breeding programme
increased with ENU dosage. The median number of offspring per ENU-treated C57BL/6J male in standard matings with
C3H/HeH females decreased with increasing dosage. The two most important underlying causes for lower male fecundity
were increased infertility in the highest dosage group and reduced numbers of litters born to the remaining fertile C57BL/6J
males due to a higher incidence of morbidity. These findings have allowed us to refine breeding strategy. To maximize the
number of offspring from each ENU-treated male, we now rotate productive males between two cages to expose them
to more females. This optimizes the number of mutation carrying offspring while reducing the number of ENU-treated
males that must be generated.
Keywords: N0-ethyl-N0-nitrosourea, mouse mutagenesis, pathology, breeding management
Laboratory Animals 2009; 43: 1–10. DOI: 10.1258/la.2008.007072
Phenotype-driven screens using chemical mutagens, such as
N0-ethyl-N0-nitrosourea (ENU), have provided a powerful
means of investigating genetic causes of heritable pheno-
types. The principles of ENU mutagenesis and the location
of major mutagenesis centres worldwide have been recently
reviewed.1 Mouse ENU mutagenesis has increased the pool
of mutants in many areas of biology, helped identify novel
genes involved in physiological processes and disease, and
assisted in assigning functions to genes.2 The contribution
of ENU mutagenesis to different areas has been the
subject of an increasing number of specialist reviews, for
example in host defence, allergy and autoimmunity,3 cranio-
facial abnormalities,4 male infertility5 and behaviour.6
ENU is a commonly used mutagen for phenotype-driven
screens in mice. As an alkylating agent its ethyl group is
transferred to nucleophilic sites on each of the four nucleo-
tides of DNA. This results in mispairing at the next round
of DNA replication. ENU predominantly mutates A:T base
pairs, and in mouse phenotypic screens approximately
60% of the mutations detected are A:T to T:A transitions
or A:T to G:C transversions. In descending order of occur-
rence, ENU produces missense, nonsense and splice-site
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mutations and these tend to occur in genes with longer
coding sequences and higher exon numbers.2
The most important factors in the design of a mutagenesis
experiment are the rate at which germline mutations are
induced and the ability to recover healthy, fertile male
mice for breeding. Several studies have been published on
optimizing ENU dosage in different inbred strains of
mouse and these are summarized in recent reviews.7,8
Although the exact dose that produces the highest mutation
frequency may vary from one strain to another when admi-
nistered in a single dose, increasing the dose of ENU
increases the mutation rate. However, this effect does not
remain linear at high, single doses. Instead, the maximum
efﬁciency is achieved when high doses are administered in
a fractionated form with a short period separating each
injection, typically a week.
Published data on the pathology of ENU-treated males in
the context of a mutagenesis programme are generally scant.
In one of the few examples, a tumour survey in retired
ENU-treated (C57BL/6  CBA) F1 males, lung tumours,
thymoma (taken as a synonym for thymic lymphoma) and
liver tumours were the most common and skin, kidney,
prostate and colon tumours occurred, but were less fre-
quent.7 In this paper, we have explored the breeding and
pathology records from our experience with the mutagen-
esis programme at the Medical Research Council (MRC)
Harwell to optimize the programme by developing breed-
ing management practices and to help address welfare
issues. This paper is a retrospective case-control study of
the breeding and fate of 760 male ENU-mutagenized
mice (BALB/cAnNCrl and latterly C57BL/6J) and a more
detailed analysis of tumour pathology in 226 of these
mice. We have focused on how ENU treatment affects life-
time fecundity in relation to ENU-induced pathology,
especially clinically important tumour entities that necessi-
tated premature culling. This information has been used to
reﬁne the breeding programme.
Materials and methods
Study design
The MRC Harwell operates phenotype-driven dominant
and recessive screens. During the course of the early MRC
mutagenesis projects, the inbred strain of mice used was
BALB/cAnNCrl. For the latter mutagenesis projects com-
mencing in 2004, C57BL/6J was the major strain used
though smaller numbers of BALB/cAnNCrl, BALB/cByJ
and CeH/HeH were also used.
Three ENU dosage regimens were used. The ENU dose
was titrated in an attempt to optimize mutagenic rate in
offspring as determined by heritable phenotypes. The
experimental aim was to be just above the borderline of
infertility as higher ENU doses increase the mutation
frequency. The numbers of mice of each strain used in
each dosage regimen and necropsy sampling statistics are
given in Table 1. A general overview of the timeline for
the programme is given in Figure 1a.
Mice, husbandry and health screening
The humane care and use of mice in the rederivation pro-
gramme was conducted under the Home Ofﬁce regulations.
The earlier MRC Harwell mutagenesis projects were per-
formed in a largely conventional mouse house facility;
however, the ENU-treated mice were kept in individually
ventilated cages (IVCs). This old low health status mouse
house has now been replaced by a new high health status,
mouse only, speciﬁc pathogen free (SPF) barrier facility,
the Mary Lyon Centre (MLC). The new centre also has
digital record-keeping that has greatly facilitated data
mining.
BALB/cAnNCrl males were purchased from Charles
River and imported as 4–6-week-old mice. They were pro-
tected from exposure to infectious agents (see below) by
housing them in IVCs (Charles River Laboratories UK,
Margate, UK) in a 12 h light/dark (07:00–19:00 light
phase) cycle at 19–238C and 45–65% relative humidity on
grade 6 sawdust bedding (Datesand Ltd, Manchester, UK).
All equipment was autoclaved before use. Husbandry and
ENU treatments were performed in a class II biological
safety cabinet. Mice were fed rat and mouse No. 3 breeding
diet (Special Diets Services, Witham, Essex, UK) and pro-
vided with chlorinated water ad libitum.
Sentinels were challenged by infectious agents through
airborne exposure. Live mice were submitted to an outside
laboratory (Harlan UK Ltd Technical Services Department,
Loughborough, UK) for microbiological testing based on
FELASA recommendations.9 Health screening in the pre-
existing conventional colony (before rederivation of colonies
into the MLC) showed the presence of mouse hepatitis virus
( judged by histology to be enteropathic strains), mouse
adenovirus type 2, Theiler’s murine encephalomyelitis
virus, the intestinal ﬂagellates Spironucleus muris and
Tritrichomonas muris, pinworms, Helicobacter spp. and
Pasteurella pneumotropica.10
In some of the more recent ENU mutagenesis projects,
male C57BL/6J (Jackson Laboratories, Bar Harbor, Maine,
Table 1 Mutagenesis programme population sizes in this study
BALB/cAnNCrl C57BL/6J
Regimen (mg/kg) 23 100 33 90 33 100 23 100 33 90 33 100
Total G0 mice 326 100 48 49 135 102
Found dead 22 12 0 3 10 19
Culled sick 171 50 40† 20 74 72†
(Full necropsy) (74) (32) (1) (17) (49) (53)
Because this dosage was not tolerated by BALB/cAnNCrl mice this was discontinued
†Includes mice that were culled after losing 20% body weight acutely post-treatment and excluded for further analysis (36 BALB/cAnNCrl and 1 C57BL/6J)
................................................................................................................................................
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USA) mice were used from a SPF colony established in the
MLC rederived by embryo transfer as described.10 Mouse
husbandry in the MLC was essentially the same as in
the pre-existing mouse facilities except that the mice were
housed in Techniplast IVCs (Techniplast UK Ltd,
Kettering, UK) and the diet was irradiated.
The microbiological screening programme in the MLC
involves sending mice from sentinel cages (one per 56
cages) that are challenged with samples of dirty bedding
from separate columns in each rack on an eight-week
rotation as previously described.11 Health screening has
shown that the SPF status described above has been main-
tained since the facility opened more than two years ago.
ENU treatment and mouse breeding
As the BALB/cAnNCrl in the earlier mutagenesis projects
were imported at approximately six weeks of age, they were
assigned an estimated birth date. Records of exact birth dates
were available for the C57BL/6J and BALB/cAnNCrl males
bred in the MLC. At approximately 10–12 weeks of age
(target 10weeks), ENUdoseswere administered intraperitone-
ally at weekly intervals: 3  90 mg/kg or 2  100 mg/kg in
BALB/cAnNCrl males and 3  90 mg/kg, 2  100 mg/kg or
3  100 mg/kg in C57BL/6J males (Figure 1a). These ‘gener-
ation zero’ ENU-treated males are referred to hereafter as G0
males to distinguish them from their ﬁrst generation offspring
hereafter termed as G1 mice.
Successful ENU treatment causes a period of sterility of
approximately eight weeks starting 3–4 weeks post-
treatment12 reﬂecting exposure of pre-spermatid stages
and signiﬁcant germcell death. For the ﬁrst three weeks,
post-injection progeny may arise from spermatozoa that
were in the later stages of development when exposed to
ENU. Therefore, ENU-treated males were test-bred (one
male and one female) with similarly aged females from
week 4 to week 11 after the last dose. The females from
these matings were culled at 11 weeks and examined at
postmortem for the presence of fetuses. The males were
judged to have regained fertility very early (see below) if a
Figure 1 (a) Major timeline events for G0 ENU-treated male mice used for the phenotype-driven screens. Starting at 10 weeks each mouse was injected intra-
peritoneally with ENU at weekly intervals. The regimens employed were two doses of 100 mg/kg at one-week intervals, three weekly doses of 90 mg/kg or three
weekly doses of 100 mg/kg. (b) Categories of males lost to the breeding programme for C57BL/6J and BALB/cAnNCrl strains. The number of mice culled sick or
found dead increases with ENU dose. (c) In BALB/cAnNCrl mice the highest dosage regimen was poorly tolerated and resulted in a high percentage of mice
failing to regain fertility. These were excluded from analysis in (b) for clarity. A similar effect is seen in C57BL/6J mice which were analysed in more detail
(Figure 3)
................................................................................................................................................
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pregnancy was detected and the males were subsequently
withdrawn from the programme.
At 12 weeks after ENU treatment, males were then set up
for matings with two C3H/HeH females with an aim to
produce 50–60 offspring. A target of 50–60 offspring was
chosen to avoid the theoretical possibility of producing mul-
tiple identical mutations in offspring due to the oligoclonal-
ity of ENU-mutagenized spermatogonial stem cells that
repopulate the testis following ENU treatment. ENU treat-
ment can result in poor fertility in G0 males (see below),
so the number of G1 offspring produced in each mating
was carefully monitored. If an ENU-treated male did not
produce offspring in two months, or was a poor breeder
(i.e. had one litter but had not produced a litter for 3
months), the decision on whether to continue with the
mating was made based on the number of active matings
in the breeding colony as a whole and the availability of
new replacement ENU-mutagenized G0 males. In a later
pilot study to increase male productivity, some
ENU-treated males were rotated between two cages each
with two C3H/HeH females.
Approximations of the efﬁcacy of ENU treatment were
made at regular intervals as the number of heritable pheno-
types per G0 male. This is used for guidance in programme
management meeting requirements for the various
screens. Because of the differences in the screen protocols,
like-for-like inter-group comparisons cannot be made for
the output of the various screens and are, therefore, refrac-
tory to rigorous statistical analysis. Furthermore, the
various heritable mutations are usually in various stages
of mapping again complicating rigorous analysis.
Case definitions for analysis of breeding
and pathology
To analyse the breeding and pathology data for ENU-treated
males, mice were categorized as those ‘found dead’ (i.e.
sudden unexpected death without premonitory signs),
‘culled sick’, ‘culled regained fertility too early’ or ‘culled
did not regain fertility’. The remaining category ‘culled
other’ consisted of mice that were culled because they were
poor breeders or those that had reached their required
offspring target (50 progeny for each G0 male), males
that were injured by ﬁghting or were priapistic. The case
deﬁnition of culled sick included both neoplastic causes
and some non-neoplastic causes of morbidity, although this
latter category comprised ,5% of cases categorized as
‘culled sick’. Cases that were excluded from analysis were
males with acute post-treatment toxicity (.20% weight loss
was considered as grounds for culling).
Welfare assessments, necropsy and histology
ENU-treated mice were examined every day at 08:00 h and
14:30 h and those which were found ill (clinical signs most
often noted were rapid respirations, hunched, piloerect)
were culled immediately by an overdose of barbiturate
administered intraperitoneally (Pentoject, Animalcare,
York, UK). They were weighed, then necropsied and gross
pathology ﬁndings were recorded. Histological analysis
and tissues examined were as previously described.11
Later, testes and sternebrae were included as additional
tissues. Testes were collected and ﬁxed in Bouins solution
for 8 h. Bones were decalciﬁed in Formical (Decal Corp,
Congers, NY, USA) for 48 h. Tissues were embedded in
wax and 4 mm sections were prepared. Sections were
stained with haematoxylin & eosin (H&E).
To compare the incidence of lymphoma in ENU-treated
C57BL/6J males with spontaneous rates in untreated
males, 28 one-year-old retired breeders from the same
stock colonies were euthanized and examined at necropsy
for gross tumour burden. The mediastinum including the
thymus lobes were ﬁxed and examined histologically.
Tissue array manufacture and immunohistochemistry
Tumours were cored in duplicate (2  600 mm cores) from
donor formalin-ﬁxed parafﬁn-embedded tissue blocks into
recipient parafﬁn blocks using an automated Beecher
arrayer (Beecher Instruments, Sun Prairie, WI, USA) accord-
ing to manufacturer’s protocols. After tempering the block
overnight, 5 mm sections were cut onto APES
(3-aminopropyltriethoxysilane)-coated slides for immuno-
histochemical staining. Additional sections were stained
by H&E and assessed for adequate tumour representation.
All immunohistochemistry was performed on the Ventana
Discovery automated stainer (Ventana, Tucson, AZ, USA).
For CD3 immunostaining, sections were pretreated with
alkaline protease 0.03 U/mL for 10 min at 378C, then heat-
treated with cell conditioning buffer (Tris/EDTA/Borate
pH 8.5; Sigma-Aldrich, Gillingham, UK) for 16 min at
958C. Primary antibody (CD3, SP7 clone, rabbit monoclonal
antibody, Vector Laboratories, Peterborough, UK) was used
at a dilution of 1:200 for 20 min and followed by washing
and biotinylated secondary antibody staining for 8 min.
Streptavidin-peroxidase conjugates were applied for
16 min and visualized using 3,3-diaminobenzidine tetrahy-
drochloride with copper enhancement. All incubations were
performed at 378C. For B220 immunostaining, sections were
heat-treated with cell conditioning buffer (Tris/EDTA/
Borate pH 8.5) for 28 min at 958C. Primary antibody (B220
rat polyclonal antibody, R&D systems, Abingdon, UK) at
a dilution of 1:100 and staining and subsequent treatment
was similar to CD3 immunostaining. All incubations were
performed at 378C. Immunohistochemical staining was
assessed by a histopathologist on a semi-quantitative basis
according to percentage of cell stained and intensity of stain-
ing, i.e. negative, weakly positive, moderately positive or
strongly positive. An additional assessment of the percen-
tage of total tumour cells positive for each marker was
made.
Statistical analysis
Dosage effects on tumour latencies were analysed by the
analysis of variance (ANOVA) across multiple groups or
by a two-sample t-test. Analyses of G1 offspring produced
per G0 male were made using the non-parametric equival-
ent, the Kruskal-Wallis test or by a two-sample Wilcoxon’s
rank test. Contingency analysis was performed on
................................................................................................................................................
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lymphoma incidences using the Fisher’s exact test. In all
analytical methods P, 0.05 was considered statistically
signiﬁcant.
Results
ENU-induced pathology
The higher ENU dosage regimens (3  90 mg/kg and 3 
100 mg/kg) were associated with an increasing percentage
of C57BL/6J and BALB/cAnNCrl males that were culled
due to illness (‘culled sick’) or were found dead without pre-
monitory signs (Figure 1b). However, in BALB/cAnNCrl
males there was an increasing dose-dependent proportion
of mice that never regained fertility (Figure 1c). Therefore,
this regimen was discontinued prior to initiating the pathol-
ogy studies. In the earlier mutagenesis projects conducted in
the old mouse house, some batches of ENU-mutagenized
BALB/cAnNCrl males were culled because of acute 20%
weight loss after ENU treatment (Table 1), but this has not
recurred under SPF conditions.10
Morbidity and mortality in the vast majority (.95%) of the
G0 mice we studied were due to the development of neo-
plasia. A few individuals had conditions such as hydrone-
phrosis, bite wounds or priapism (categorized as ‘culled
other’ for subsequent analysis). However, even these mice
were usually found to have some additional occult tumour
burden, usually lung adenomas. By far, the most common
tumours in both the BALB/cAnNCrl and C57BL/6J strains
were multisystemic lymphomas and lung tumours (see
below, Table 2). Small benign lung adenomas were com-
monly found in ENU-treated C57BL/6J and BALB/cAnNCrl
mice of all ages, but by gross and histological assessment
these were not sufﬁciently large or numerous enough to be
classiﬁed as a primary cause of morbidity or mortality. In
contrast, large lung carcinomas were likely to be clinically sig-
niﬁcant in BALB/cAnNCrl mice, as clinical signs could not be
attributed to multisystemic lymphoma (only three of 42 of
these mice had multisystemic lymphoma). Some morbidity
in C57BL/6J mice was associated with intestinal tumours
causing a degree of bowel obstruction, and the incidence of
such tumours appeared to increase with ENU dosage. The
incidence of intestinal tumours appeared lower in BALB/
cAnNCrl males. In contrast, renal neoplasia was a common,
clinically non-signiﬁcant ﬁnding in both BALB/cAnNCrl
and C57BL/6J males. Fewer than 7% of mice had neoplastic
lesions in other tissue origins, for instance there were ﬁve
myeloid leukaemias and two oligodendrogliomas (data not
shown). Other pathological ﬁndings included a spectrum of
endothelial lesions in the spleen (7–27% in both strains; the
most common was angiectasis, then haemangioma, whereas
haemangiosarcoma was rare) and liver (biliary) cysts
(9–21% incidence in both strains).
A subset of lymphomas fromC57BL/6J (n ¼ 33) andBALB/
cAnNCrl (n ¼ 32) mice were further analysed by pathological
examination of tumour morphology and immuno-
histochemistry of tumour samples on tissue arrays. Tumours
were assessed for positivity for a pan-T-cell marker, CD3,
and a pan-B-cell marker, B220. One hundred percent
of tumours that were immunophenotyped in this manner
(n ¼ 65) were found to be positive for CD3 and negative for
B220, and all were cytologically blastic, predominantly
lymphoblastic, typical of T-lymphoblastic lymphoma. Most
T-lymphoblastic lymphoma cases were presented as a
space occupying (.5 mm) mediastinal mass with intra-
thoracic direct spread to epicardium, tracheobronchial
lymph node, pleura, perivascular and peribronchiolar sites
in lung, diaphragm and intercostal muscle. A large pro-
portion had extrathoracic involvement (in approximate
descending order), liver. spleen. kidney. lymph node.
meninges. adrenal; 49% (n ¼ 99) of the C57BL/6J males
had additional sternebral bone marrow involvement by
lymphoma.
Temporal pattern of tumour development in
relation to the breeding programme
The potential impact of tumourigenesis on the breeding pro-
gramme was evaluated by plotting the date of necropsy
or sudden unexpected death after ENU treatment. This
latency for the four most common tumours is presented in
Figure 2. In cohorts of BALB/cAnNCrl mice, there was an
early cluster of lymphomas followed by a later cluster of
lung carcinomas. In contrast, in C57BL/6J mice morbidity
Table 2 Major tumour incidences in G0 mice culled sick
BALB/cAnNCrl C57BL/6J
Regimen (mg/kg) 23 100 33 90 23 100 3 3 90 33 100
Lymphoma 27% (20) 69% (22)† 82% (14) 76% (37)† 100% (53)
Lung
Adenoma 51% (38) 62% (20) 47% (8) 18% (9) 47% (25)
Carcinoma 45% (33) 28% (9) – – –
Kidney
Adenoma 28% (21) 25% (8) – 14% (7) 6% (3)
Carcinoma 4% (3) 3% (1) – – –
Intestines
Adenoma 1% (1) 3% (1) 6% (1) 12% (6) 26% (14)
Carcinoma 1% (1) – 6% (1) 6% (3) –
Total (n) 74 32 17 49 53
The figure in the body of the table represents percentage incidence and in parentheses are the number of case observed of the total (n)
The incidence of lymphoma in 2  100 mg/kg dosage regimen is significantly lower in BALB/cAnNCrl males (P, 0.0001) (one-tailed Fisher’s exact test)
†Incidence of lymphoma is not significant at 3  90 mg/kg (P ¼ 0.34) (one-tailed Fisher’s exact test)
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was almost exclusively due to lymphoma early in the breed-
ing programme. In both strains, the peak of lymphoma
incidence was well within the breeding period for these
mice (Figure 2) signiﬁcantly curtailing the number of G0
mice that would produce a target of 50 progeny (see
below in this section). The signiﬁcantly later onset of lung
carcinoma in BALB/cAnNCrl mice suggests that these
lesions were far less likely to impact on the breeding pro-
gramme as many more of these mice would have lived
long enough to reach their pup limit.
Figure 2 Age-related incidence of the four most common tissue neoplasms found at necropsy. In C57BL/6J mice, morbidity is almost exclusively due to early-
onset lymphomas, though some mice develop early-onset intestinal neoplasms and late-onset renal tumours. Early-onset lymphomas are also seen in BALB/
cAnNCrl mice, but these mice also develop late-onset lung carcinomas (not seen in C57BL/6J mice) and renal tumours. Note: in this series of C57BL/6J
males did not develop lung carcinoma
................................................................................................................................................
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Although the incidence of lymphoma may be inﬂuenced
by ENU dosage, the latency was not signiﬁcantly different
between the dosage groups for either strain. For C57BL/6J
mice, the mean age for lymphoma development on each
dosage regimen were 218+8, 234+11 and 214+7 days
(mean+SEM) for the 2  100 (n ¼ 14), 3  90 (n ¼ 37) and
3  100 (n ¼ 53) mg/kg, respectively (P ¼ 0.21; ANOVA).
For BALB/cAnNCrl mice, the mean latency for lymphoma
development on each regimen were 264+15 and 255+10
days (mean+SEM) for the 2  100 (n ¼ 21) and 3  90
(n ¼ 30) mg/kg, respectively (P ¼ 0.62; ANOVA). In addition,
there was no difference in the latency of lung
carcinoma development in BALB/cAnNCrl mice for each
dosage regimen; these were 408+11 and 374+19 days for
the 2  100 (n ¼ 29) and 3  90 (n ¼ 8) mg/kg, respectively
(P ¼ 0.54; ANOVA).
In contrast to early morbidity associated with high
incidence of thymic lymphoma in ENU-treated males, a
cohort of 28 retired untreated C57BL/6J breeding males
experienced no morbidity or sudden deaths between six
months and 12 months and, at necropsy, none had any
macroscopic tumour burdens or histological evidence of
thymic lymphoma.
The effect of ENU dosage regimen on breeding
potential in C57BL/6J males
ENU administration causes a temporary period of infertility
in C57BL/6J males and also has the potential to cause
permanent infertility. ENU also induces neoplasia that
may impact the breeding potential of G0 mice either by
premature removal (e.g. infertility, morbidity, sudden
death, etc.) or subclinical neoplasia may reduce male pro-
ductivity in the terminal stages.
Each of these possible contributory factors was assessed
(Figure 3) for the C57BL/6J mice. The most dramatic per-
turbation of fecundity was evident in an apparently dose-
dependent increase in the number of G0 males that failed
to produce any offspring. This was possibly related to
the cumulative dose for each regimen, and in the highest
regimen of 3  100 mg/kg results in 40% of the males
failing to produce any offspring at all (Figure 3a). This
was not due to a dose-dependent increase in the time
from the end of ENU dosage to ﬁrst litter, as the time to
ﬁrst litter was comparable for each of the three regimens.
These were 121+ 3.1, 123+ 2.8 and 126+ 2.7 days
(mean+ SEM) for the dosage regimens 2  100 (n ¼ 21),
3  90 (n ¼ 78) and 3  100 (n ¼ 68) mg/kg, respectively
(P ¼ 0.58; ANOVA). However, the development of neo-
plasia during the breeding programme clearly resulted in
greater losses (Figure 3c) with only approximately 12%
of males treated with higher dosage regimens alive at
one year compared with approximately 40% at lower
dosages. This resulted in an altered breeding proﬁle
(Figure 3b) as a consequence of dose-dependent lower
pup production. Pup production decreased with increas-
ing ENU dosage (including those which produced no off-
spring); for each group the median pup production was
29.5, 10 and 5 pups per G0 male for the dosage regimens
2  100 (n ¼ 22), 3  90 (n ¼ 119) and 3  100 (n ¼ 113)
mg/kg, respectively (P ¼ 0.0013; Kruskal-Wallis test).
The corresponding means were 28.6, 20.2 and 12.1 pups
per G0 male.
The most important contributory factor to the reduction
in fecundity of males that did breed was a reduction in
the number of litters produced (Figure 3d) due to increased
incidence of morbidity in the highest ENU dosage cohort.
The average litter size (Figure 3e) and frequency of litter
production (Figure 3f) were not altered. We assessed the
effect of subclinical lymphoma in C57BL/6J on male pro-
ductivity (assuming that C3H/HeH female fertility was
not impaired) and found C57BL/6J males showed the
same pattern of siring litters up to the time that they were
‘culled sick’ in all dosage regimens (data not shown).
Histological assessment of testes in C57BL/6J males culled
sick (n ¼ 76) found that there was mild focal seminiferous
tubule atrophy in only 5% of cases indicating that repopula-
tion of the testes was complete and histologically unremark-
able in the vast majority of cases by the time of postmortem
examination.
Effect on productivity of providing extra females
to fertile ENU-treated C57BL/6J males
In view of the limited breeding lifespan of ENU-treated
males in the 3  100 mg/kg dosage group, a pilot study
was undertaken to determine the effect of providing more
female mates. Once males had sired their ﬁrst litter(s),
they were then rotated between this cage and a second
cage with two C3H/HeH females. The median number
of litters increased from three to seven (P ¼ 0.0007;
Wilcoxon’s test) and the median number of offspring from
13 to 30 (P ¼ 0.0008; Wilcoxon’s test) (n ¼ 65 for two
female mates, n ¼ 33 for four female mates).
Discussion
We present here the ﬁndings from more than ﬁve years data
on the effects of ENU dosage regimens on the breeding per-
formance and incidence of tumour pathology in BALB/
cAnNCrl and C57BL/6J mice mutagenized in the ENU
mouse mutagenesis programmes at MRC Harwell. We go
on to describe what inﬂuence the ﬁndings of these studies
have had on our management practices.
The management of large-scale mutagenesis pro-
grammes, such as those at Harwell, are driven by
phenotype demand from the various screens that are under-
taken. These are subject to regular review and management
practices alter to meet these demands. The value of review-
ing breeding and pathology, such as with the current study,
is to provide insight into the fate of the G0 males in different
dosage regimens and the impact on production of G1
progeny. As it is known that ENU dosing increases the
mutation rate linearly in the dose range we used,13 the
optimal dose regimen is the highest possible that does not
reduce fertility or welfare of the mice to an unacceptable
extent.
Much of the published ENU literature focuses on mechan-
isms of mutagenesis, mutation rates and speciﬁc mouse
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Figure 3 Decreased reproductive potential of ENU-treated C57BL/6J mice. ENU treatment decreases the reproductive potential by three possible mechanisms,
impairment of fertility, premature death and a terminal decline in productivity. (a) Increasing dosage regimen, or more precisely increasing cumulative dose,
results in more males rendered permanently infertile. (b) Loss of reproductive potential through premature death is manifested in fewer males producing the
set target of 50 progeny. (c) Survival analysis demonstrates that in mice treated with 3  100 mg/kg loss from the breeding programme is through higher
tumour incidence rather than significantly decreased tumour latency; t1
2
is comparable for dosage regimens. (d–f) Pup litter statistics for G0 males that produced
offspring. Decreased productivity in mice treated with the highest regimen is through fewer litters (d) and not from decreased litter size (e) or littering frequency (f ).
Box and whisker plots for each dosage regimen have a horizontal bar for the median values within a rectangle representing the 25th and 75th percentiles; the
whisker represents the minimum and maximum values. Numbers above each box and whisker plot indicate sample sizes. K-W ¼ Kruskal-Wallis test for non-
parametric comparison across all three regimens. Two-sample analyses were performed using the Wilcoxon’s rank test. Indicates statistical significance
................................................................................................................................................
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models generated.2 There is relatively little information
regarding colony management practices and productivity
in relation to welfare and pathology. The issue of
productivity of males following ENU treatment is of con-
siderable importance in ENU mutagenesis programmes
because of the need to generate sufﬁcient numbers of G0 off-
spring for different phenotypic screens. Others have
assessed mortality in the sterile period after exposure to
ENU, and regained fertility but primarily with the view to
optimize ENU dosage regimen for each strain.7,8 Initial
studies in small cohorts identiﬁed 3  100 mg/kg as an
optimal regimen for both C57BL/6J and BALB/cJ strains
with regained fertility rates of 6/10 (60%) and 5/6 (83%)
in males for each strain, respectively.8 Although the
BALB/c is a different substrain from the one in our study,
the C57BL/6J strain is comparable. In our larger sample
size, we can conﬁrm a relationship between cumulative
dose and infertility rates suggested in smaller cohorts of
these strains. Indeed, a more recent study of comparable
population size, but in C3HeB/FeJ mice,14 shows a similar
ﬁnding to ours and is also in agreement with previously
published rates in smaller cohorts of this inbred strain.8
We were particularly interested in our study to extend this
analysis and to explore the components of lifetime fecund-
ity: regained fertility and lifetime productivity.
One good example of detailed analysis of fecundity in
chemically mutagenized males is that by Russell et al.12
but this focuses on the immediate post-treatment effects of
ENU on spermatocytes. Male productivity was measured
directly in (101/R1xC3H/R1) F1 males immediately after
ENU treatment with 50 mg/kg, 100 mg/kg or 250 mg/kg,
in seven, sequential one-week matings. This experiment
showed a decrease in average litter size with time, providing
an approximate indication of lethality in G1 offspring,
whereas decrease in litter number per male may represent
morbidity and fewer copulations, germcell killing and/or
lethality.12 The highest ENU dose 250 mg/kg reduced
the number of litters. Both ENU and another chemical
mutagen MNU (N0-methyl-N0-nitrosourea also studied in
this work) have mutagenic effects on stem-cell spermatogo-
nia and elicit very high mutation rates in differentiating
spermatogonia when measured by speciﬁc-locus assays,
hence the mutagenic effects seen from early matings in the
seven-week post-treatment period.
In a similar way, we have examined litter frequency, size
and number of ENU-treated males after they have regained
fertility. Using these indices coupled with the results of the
pathology analysis, we can also show loss from the breeding
programme through morbidity and premature death. The
biggest impact of ENU on the fecundity or lifetime breeding
potential of G0 males was the adverse effect of cumulative
ENU dose, increasing the number of males being rendered
permanently infertile. Subsequently, the loss from the breed-
ing programme through morbidity and premature death has
a greater effect than a modest decline in productivity during
subclinical stages of lymphoma. This is supported by data
from those males that did breed indicating that while
neither average litter size nor littering frequency were
affected, the number of litters per G0 male was signiﬁcantly
decreased in the highest dosage regimen.
The types of ENU-related pathology are as follows.
In the earlier mutagenesis experiments, acute post-
treatment toxicity with ENU treatment resulting in 20%
weight loss was a problem when BALB/cAnNCrl mice
were exposed to infection as a result of IVC barrier break-
down in an otherwise low health status mouse. ENU is a
stem-cell mutagen and affects haematopoietic stem cells
causing immunosuppression.7 In our low health status
conventional mouse colony this appeared to predispose
to MHV infection. This complication of acute post-
treatment toxicity has been overcome by rederivation of
the stocks and performing ENU treatments in SPF con-
ditions in the MLC.10 The major pathology was tumouri-
genesis and in our analysis we found that in both BALB/
cAnNCrl and C57BL/6J strains, ENU-treated males had
a very high incidence of malignant T-lymphoblastic lym-
phoma. In addition, in BALB/cAnNCrl lung carcinoma
was also important. The case for lymphoma being
induced by ENU is clear-cut because the very high inci-
dence (.75% of those culled sick) at a relatively young
age is considerably greater than background incidence
(9–34%) in untreated BALB/cAnNCrl and C57BL/6J
mice on two-year ageing studies.15 Furthermore, our
survey of 28 retired untreated C57BL/6J breeding males
found no morbidity or sudden death between six months
and 12 months and no thymic lymphomas.
The incidence of other less common tumours can be
age-related and we are cautious not to over-interpret the
differences between strains because early lymphomas
abrogate the development of a wider tumour spectrum.
Furthermore, it is possible that low health status of the con-
ventional BALB/cAnNCrl mice in the earlier mutagenesis
experiments has had some effect on the development of
tumours. In both BALB/cAnNCrl and C57BL/6J, the peak
of lymphoma incidence within the breeding period pro-
duces a signiﬁcant decrease in productivity. Lymphoma
incidence in BALB/cAnNCrl and C57BL/6J mice ‘culled
sick’ was similar at the 3  90 mg/kg dosage (no data are
available for comparison with the 3  100 mg/kg dosage),
but in the 2  100 mg/kg dosage group, the incidence of
lymphoma in BALB/cAnNCrl was lower than in C57BL/
6J mice (27% vs. 82%, P, 0.0001, Fisher’s exact test;
Table 2). Whether this represents a strain-speciﬁc lower
dosage threshold for ENU-induced lymphoma in C57BL/
6J mice is unclear. The incidence of spontaneous lymphoma
BALB/cAnNCrl and C57BL/6J mice is approximately the
same.15 The putative mechanism of ENU-induced lympho-
magenesis may be associated with perturbation of genes
in DNA repair and tumour suppressor pathways,16–19 and
it will be interesting to see if these mechanisms play a role
in strain-speciﬁc susceptibility. Irrespective of the ENU
dosage regimen used, the majority of ENU-treated mice
were culled on welfare grounds before being retired from
the breeding programme.
In recognition of the early onset of lymphoma in
ENU-treated males, and as part of the continual monitoring
of our practices, we have implemented a major reﬁnement
to our current mutagenesis programme. Once G0 males
have sired a litter, we now rotate them to a second cage
that holds two C3H/HeH females. The rationale is to
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maximize productivity within a limited breeding lifetime. In
C57BL/6J males treated with 3  100 mg/kg ENU this is,
on average, 88 days between the birth of the ﬁrst litter(s)
(126+3 days) and lymphoma-associated death (214+7
days). This reﬁnement in breeding strategy has increased pro-
ductivity by more than two-fold.
This retrospective case-control study of breeding and
pathology in an ongoing ENU mutagenesis programme
does not attempt to address the question of efﬁciency of
mutagenesis for different dosage regimens using standard
measures, such as a speciﬁc-locus test12 or the number of
molecularly characterized mutations per mutagenized
gamete. An assessment can be made after several more
years’ work to identify all the mutated genes underlying
the phenotypes revealed in the screens. Truly comparative
estimates of ENU dosage and mutagenesis efﬁciency will
have to take into account the diverse and changing collec-
tion of dominant and recessive phenotypic screens across
all Harwell mutagenesis projects. Under these circum-
stances, the question of cost/beneﬁt analysis cannot be com-
pletely resolved because an ENU dosage that might have a
high impact on animal welfare (cost) might be very efﬁcient
at producing mutant pedigrees (high scientiﬁc beneﬁt). The
closest we can come to reconcile this problem is to use pub-
lished data as a guideline for the highest tolerable ENU dose
to produce the greatest mutagenesis efﬁciency. The question
then becomes how to maximize the productivity of
ENU-injected males because one major outcome of the
highest dose will be increased sterility. The measurement
and analysis of breeding success and the pathology out-
comes then becomes the key to identifying timelines to
breed as many offspring in the shortest period.
In conclusion, to our knowledge, this is the ﬁrst
large-scale analysis of deleterious effects of ENU dosage
regimens on the breeding performance, pattern and inci-
dence of tumour pathology in an ENU mouse mutagenesis
programme. This has provided new insights into lifetime
productivity and allowed us to reﬁne our breeding strategy
to improve breeding productivity while minimizing the
numbers of males that are treated with ENU.
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